Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope? [PDF]
Frontiers in Oncology, 2021 BackgroundHead and neck squamous cell carcinoma (HNSCC) carries poor survival outcomes despite recent progress in cancer treatment in general. Angiogenesis is crucial for tumour survival and progression.
Aini Hyytiäinen +13 more
doaj +3 more sources
Cardiotoxic effects of angiogenesis inhibitors. [PDF]
Clin Sci (Lond), 2021 The development of new therapies for cancer has led to dramatic improvements in survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising treatment for a wide range of malignancies.
Dobbin SJH +4 more
europepmc +7 more sources
Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. [PDF]
PLoS ONE, 2013 Current inhibitors of angiogenesis comprise either therapeutic antibodies (e.g. bevacicumab binding to VEGF-A) or small molecular inhibitors of receptor tyrosin kinases like e.g. sunitinib, which inhibits PDGFR and VEGFR.
Sabine B Weitensteiner +8 more
doaj +13 more sources
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. [PDF]
Cell Commun Signal, 2022 Abnormal vasculature is one of the most conspicuous traits of tumor tissue, largely contributing to tumor immune evasion. The deregulation mainly arises from the potentiated pro-angiogenic factors secretion and can also target immune cells' biological ...
Ansari MJ +11 more
europepmc +2 more sources
Angiogenesis Inhibitors in Small Cell Lung Cancer. [PDF]
Front Oncol, 2021 Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung ...
Montanino A +14 more
europepmc +2 more sources
The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis [PDF]
Journal of Ovarian Research, 2022 Objective To investigate the efficacy and safety of angiogenesis inhibitors in the treatment of recurrent ovarian cancer (OC). Methods Electronic databases including PubMed, Web of Science, and the Cochrane Library were searched to find eligible studies ...
Chunmei Zhang, Wancheng Zhao
doaj +2 more sources
Journal of Hematology & Oncology, 2016 Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) directed against the vascular endothelial growth factor (VEGF) or its receptors have been investigated in several studies for the treatment of advanced gastric cancer (GC). In the
Jing Yu +5 more
doaj +2 more sources
Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma [PDF]
IJU Case Reports, 2020 Introduction Nivolumab is effective for advanced renal cell carcinoma; however, reports are limited wherein nivolumab is combined with sequential therapy of angiogenesis inhibitors and metastasectomy.
Hiroki Hagimoto +8 more
doaj +2 more sources
Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis [PDF]
BMC Pulmonary Medicine, 2023 Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs).
Di Hu +6 more
doaj +2 more sources
Cardiovascular Toxicity of Angiogenesis Inhibitors Among Patients With Cancer in Taiwan: A Nested Case‐Control Study [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Research on the cardiovascular toxicity of angiogenesis inhibitors among patients with cancer in Taiwan is lacking. This observational study explored the risk of major adverse cardiovascular events (MACEs) associated with angiogenesis ...
Yen‐Chou Chen +4 more
doaj +2 more sources